Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
12/1/2023
0:00
15:01
Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ.
Related Content:
Altri episodi di "JAMA Author Interviews"
Non perdere nemmeno un episodio di “JAMA Author Interviews”. Iscriviti all'app gratuita GetPodcast.